DALLAS, Oct. 1, 2026 /PRNewswire/ -- Nanoscope Therapeutics, Inc. ("Nanoscope"), a biotechnology company focused on developing and commercializing novel, disease–agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has accepted for review, and granted priority review to, the Company's New Drug Application (NDA) seeking marketing approval from the Ministry of Health, Labour and Welfare (MHLW) of MOGENRY^®(sonpiretigene isteparvovec, MCO-010), an optogenetic gene therapy designed for vision restoration, for the treatment of inherited retinal dystrophies (IRDs).